Holders — by stockHoldings — by fund
Fairmount Funds Management LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001802528
$1.51B
disclosed book value
12
positions
23.3%
largest position share
Positions, as of 2026-06-30
top 12 of 12 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | ORKAORUKA THERAPEUTICS INC | 3.7M | $352.6M | 23.3% |
| 2 | DNTHDIANTHUS THERAPEUTICS INC | 2.5M | $247.3M | 16.3% |
| 3 | DAMORA THERAPEUTICS INC | 8.7M | $226.6M | 15% |
| 4 | COGTCOGENT BIOSCIENCES INC | 5.5M | $213.0M | 14.1% |
| 5 | JBIOJADE BIOSCIENCES INC | 4.6M | $101.2M | 6.7% |
| 6 | ELVNENLIVEN THERAPEUTICS INC | 1.9M | $94.2M | 6.2% |
| 7 | VRDNVIRIDIAN THERAPEUTICS INC | 5.1M | $93.5M | 6.2% |
| 8 | ZBIOZENAS BIOPHARMA INC | 2.4M | $59.9M | 4% |
| 9 | CRESCENT BIOPHARMA INC. | 2.7M | $49.5M | 3.3% |
| 10 | APGEAPOGEE THERAPEUTICS INC | 298,647 | $39.6M | 2.6% |
| 11 | FTHFAETH THERAPEUTICS INC | 722,020 | $18.1M | 1.2% |
| 12 | IKTINHIBIKASE THERAPEUTICS INC | 8.6M | $17.5M | 1.2% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.